Table 3.

Results of the univariable analysis comparing anti-RNAP3+ patients with or without synchronous cancer. Values are no./available data no. (%) unless otherwise specified.

CharacteristicsAnti-RNAP3+ with Synchronous CancerAnti-RNAP3+ without Synchronous CancerpOR (95% CI)
Age at disease onset, yrs, mean (SD), (n available)65.3 (10.0) (12)49.3 (13.3) (128)< 0.001
Male6/14 (42.9)28/136 (20.6)0.058
Diffuse cutaneous subtype13/14 (92.9)67/121 (55.4)0.00810.5 (1.33–82.6)
Peak mRSS, 0/51 to 51/51, mean (SD), (n available)23.3 (13.7) (12)21.0 (11.8) (83)0.537
Time to peak of mRSS, mos, mean (SD), (n available)12.0 (14.7) (12)14.5 (17.8) (83)0.587*
Gastroesophageal reflux disease8/14 (57.1)92/143 (64.3)0.593
GAVE3/14 (21.4)10/143 (7.0)0.061
Scleroderma renal crisis2/14 (14.3)17/144 (11.8)0.785
  • * Log rank test, Kaplan-Meier analysis. mRSS: modified Rodnan skin score; GAVE: gastric antral vascular ectasia; anti-RNAP3: anti-RNA polymerase III antibodies.